Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer

Most papers in this section are written about various aspects of prostate cancer, and cover a wide cross‐section of subjects relating to this important topic. Interestingly there has been increasing interest by clinical oncologists in this area, and I am delighted to publish their views in this Journal. We as urologists now routinely have multidisciplinary team meetings, and find the insightful comments of the non‐urologists very helpful in the management not only of patients with prostate cancer, but also of all types of urological malignancy.

[1]  L. Klotz.  Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. , 2004, The Journal of urology.

[2]  G. Naglie,et al.  The association between patient age and prostate cancer stage and grade at diagnosis , 2004, BJU international.

[3]  C. Higano,et al.  “Osteoporosis in Men with Prostate Carcinoma Receiving Androgen-Deprivation Therapy: Recommendations for Diagnosis and Therapies,” , 2004 .

[4]  M. Mori,et al.  Delayed therapy with curative intent in a contemporary prostate cancer watchful‐waiting cohort , 2004, BJU international.

[5]  M. Cooperberg,et al.  National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[6]  A. Oberg,et al.  Fracture risk following bilateral orchiectomy. , 2003, The Journal of urology.

[7]  Matthew R. Smith.  Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma , 2003, Cancer.

[8]  E. Bergstralh,et al.  Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. , 2002, Journal of Urology.

[9]  P. Ebeling,et al.  Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit , 2002, The Medical journal of Australia.

[10]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[11]  F. Labrie,et al.  Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? , 2002, Urology.

[12]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[13]  P. Walsh,et al.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. , 2002, The Journal of urology.

[14]  P. Schellhammer,et al.  Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. , 2001, The Journal of urology.

[15]  P. Carroll,et al.  Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. , 2001, Urology.

[16]  R. Parker,et al.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  S. Tucker,et al.  Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. , 2001, The oncologist.

[18]  R. Eastell,et al.  Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.

[19]  D. Lubeck,et al.  Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. , 2000, The Journal of urology.

[20]  P. Walsh.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.

[21]  Y. Homma,et al.  Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group. , 2000, Japanese journal of clinical oncology.

[22]  D. Lubeck,et al.  Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. , 1999, Urology.

[23]  E. Seeman,et al.  Osteoporosis in Men , 1999, Osteoporosis International.

[24]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[25]  R. Sylvester,et al.  The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials , 1998, European Urology.

[26]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.